Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients (NIMES-ROC)

P

Pharma Mar

Status

Completed

Conditions

Relapsed Ovarian Cancer

Treatments

Drug: trabectedin

Study type

Observational

Funder types

Industry

Identifiers

NCT02825420

ET-D-031-14

Details and patient eligibility

About

Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug

Enrollment

220 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women aged 18 years or older.
Presence of platinum-sensitive relapsed ovarian cancer.
Treatment and treated indication according to local label SmPC and reimbursement for trabectedin and PLD treatment.
Prior treatment with a minimum of 1 cycle of trabectedin + PLD according to SmPC before inclusion in the study, and no more than 3 previous treatment lines.
Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.

Exclusion criteria